Mr. Speaker, brand name drug companies are routinely abusing the loopholes in the current patent legislation that allow an automatic two year extension of their market monopolies.
Everybody agrees that drug companies should have patent protection, but when patents expire generic drugs should be allowed on to the marketplace without costly court battles or needless bureaucratic delays. When will the industry minister close the loopholes that allow generic drugs to reach the market after patents have expired?